AbbVie’s Allergan Settles Fetzima Depression Drug Patent Suits

Sept. 15, 2021, 2:58 PM

AbbVie’s Allergan had claimed that generic versions of Fetzima proposed by Aurobindo and MSN Laboratories infringe three patents related to the treatment for major depressive disorder.

  • MSN and Aurobindo agreed to be blocked from making copies until patents have expired or have been invalidated, “absent a license or other authorization” by Allergan, according to stipulations and orders approved Tuesday in federal court in Newark, New Jersey
  • Bench trial had been set to begin Sept. 7
    • AbbVie sent confidential letter to judge that day; it remains sealed
  • Allergan filed complaints starting in October 2017; MSN and Aurobindo were only remaining ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.